26.1.2007   

EN

Official Journal of the European Union

C 18/4


Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2007/C 18/03)

—   Issuing, maintenance or modification of a national marketing authorisation

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

13.12.2006

Glucomed

See Annex I

See Annex I

14.12.2006

13.12.2006

Agopton

See Annex II

See Annex II

14.12.2006

—   Suspension of a national marketing authorization

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

19.12.2006

Cetirizine Nordic Drugs

See Annex III

See Annex III

21.12.2006

19.12.2006

Cetirizine Dermapharm

See Annex IV

See Annex IV

21.12.2006

19.12.2006

Cetirizine Apex

See Annex V

See Annex V

21.12.2006


(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.


ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES

Member State

Marketing Authorisation Holder

Applicant

Invented name

Strength

Pharmaceutical Form

Route of administration

Austria

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Belgium

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Cyprus

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Czech Republic

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Denmark

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Estonia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Finland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

France

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Germany

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Greece

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Hungary

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Ireland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Italy

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Latvia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Lithuania

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Luxemburg

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

The Netherlands

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Poland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Portugal

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Slovakia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Spain

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Sweden

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

United Kingdom

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Iceland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Norway

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use


ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State

Marketing Authorisation Holder

Product name

Strength

Pharmaceutical form

Route of administration

Austria

Takeda Pharma Ges.m.b.H.

Seidengasse 33-35

A-1070 Vienna

AGOPTON

15 mg

Capsule

Oral use

AGOPTON

30 mg

Capsule

Oral use

AGOPTON Rapid

15 mg

Oro-dispersible tablet

Oral use

AGOPTON Rapid

30 mg

Oro-dispersible tablet

Oral use

Belgium

Sanofi-Synthelabo SA NV

Dobbelenberg

5, Avenue de la Metrologie

B-1130 Brussels

DAKAR

15mg

Capsule

Oral use

DAKAR

30 mg

Capsule

Oral use

NIBITOR

30 mg

Capsule

Oral use

Denmark

Wyeth ab

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

Finland

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

France

Laboratoires Takeda SA

15, quai de Dion Bouton

F-92816 Puteaux Cedex

OGAST

15 mg

Capsule

Oral use

OGAST

30 mg

Capsule

Oral use

Sanofi-Aventis

46 quai de la Râpée

F-75601 Paris Cedex 12

LANZOR

15 mg

Capsule

Oral use

LANZOR

30 mg

Capsule

Oral use

Germany

Takeda Pharma GmbH

Viktoriaallee 3-5

D-52066 Aachen

AGOPTON

15 mg

Capsule

Oral use

AGOPTON

30 mg

Capsule

Oral use

LANZOR

15 mg

Capsule

Oral use

LANZOR

30 mg

Capsule

Oral use

Greece

Vianex S.A.

Tatoiou Street

EL-146 71 Nea Erythrea, Athens

LAPRAZOL

15 mg

Capsule

Oral use

LAPRAZOL

30 mg

Capsule

Oral use

LAPRAZOL FasTab

15 mg

Oro-dispersible tablet

Oral use

LAPRAZOL FasTab

30 mg

Oro-dispersible tablet

Oral use

Hungary

Gedeon Richter

Gyomrói út 19-21

H-1103 Budapest

LANSONE

30 mg

Capsule

Oral use

Ireland

John Wyeth & Brother Limited

Trading as Wyeth Pharmaceuticals

Huntercombe Lane South

Taplow, Maidenhead

Berkshire SL6 0PH

United Kingdom

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON FasTab

15 mg

Oro-dispersible tablet

Oral use

ZOTON FasTab

30 mg

Oro-dispersible tablet

Oral use

Cyanamid of Great Briain Ltd.

Fareham Road

GOSPORT Hampshire PO13 0AS

United Kingdom

ZOTON

30mg

Gastro-resistant granules for oral suspension

Oral use

Italy

Takeda Italia Farmaceutici S.p.A.

Via Elio Vittorini 129

I-00144 Roma

LANSOX

15 mg

Capsule

Oral use

LANSOX

30 mg

Capsule

Oral use

LANGAST

15 mg

Capsule

Oral use

LANGAST

30 mg

Capsule

Oral use

LANSOX

15 mg

Oro-dispersible tablet

Oral use

LANSOX

30 mg

Oro-dispersible tablet

Oral use

Sigma-Tau S.p.A.

Via Pontina km. 30,400

I-00040 Pomezia, Roma

LIMPIDEX

15 mg

Capsule

Oral use

LIMPIDEX

30 mg

Capsule

Oral use

LIMPIDEX

15 mg

Oro-dispersible tablet

Oral use

LIMPIDEX

30 mg

Oro-dispersible tablet

Oral use

Wyeth Lederle S.p.A.

Via Nettunense, 90

I-04011 Aprilia (LT)

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON

15 mg

Oro-dispersible tablet

Oral use

ZOTON

30 mg

Oro-dispersible tablet

Oral use

Luxembourg

Sanofi-Synthelabo SA NV

Dobbelenberg, 5, Avenue de la Metrologie

B-1130 Brussels

DAKAR

15 mg

Capsule

Oral use

DAKAR

30 mg

Capsule

Oral use

Netherlands

Sanofi-Synthelabo B.V./Aventis Pharma B.V.

Kampenringweg 45 D-E (toren D en E)

2803 PE Gouda

Nederland

PREZAL

15 mg

Capsule

Oral use

PREZAL

30 mg

Capsule

Oral use

Portugal

Seber Portuguesa Farmacêutica, SA

Rua Norberto de Oliveira, 1 a 5

P-2620-111 Póvoa de Santo Adrião

OGASTO

15 mg

Capsule

Oral use

OGASTO

30 mg

Capsule

Oral use

OGASTO

15 mg

Oro-dispersible tablet

Oral use

OGASTO

30 mg

Oro-dispersible tablet

Oral use

Spain

Almirall Prodesfarma, S.A.

General Mitre, 151

E-08022 Barcelona

OPIREN

15 mg

Capsule

Oral use

OPIREN

30 mg

Capsule

Oral use

BAMALITE

15 mg

Capsule

Oral use

BAMALITE

30 mg

Capsule

Oral use

OPIREN Flas

15 mg

Oro-dispersible tablet

Oral use

OPIREN Flas

30 mg

Oro-dispersible tablet

Oral use

BAMALITE Flas

15 mg

Oro-dispersible tablet

Oral use

BAMALITE Flas

30 mg

Oro-dispersible tablet

Oral use

Sweden

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

United Kingdom

John Wyeth & Brother Limited

Trading as Wyeth Pharmaceuticals

Huntercombe Lane South

Taplow, Maidenhead

Berkshire SL6 0PH

United Kingdom

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON

30 mg

Gastro-resistant granules for oral suspension

Oral use

ZOTON FasTab

15 mg

Oro-dispersible Tablet

Oral use

ZOTON FasTab

30 mg

Oro-dispersible Tablet

Oral use

Iceland

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

Norway

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use


ANNEX III

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE NORDIC DRUGS 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Denmark

Nordic Drugs AB

Geijersgatan 4 C

S-200 61 Limhamn

Gardex

10 mg

Film coated tablet

Oral

Finland

Nordic Drugs AB

Geijersgatan 2A

Box 30035

S-200 61 Limhamn

Gardex 10 mg tabletti, kalvopäällysteinen

10 mg

Film coated tablet

Oral

Netherlands

Nordic Drugs AB

Box 30035

S-200 61 Limhamn

Cetirizine dihydrochloride Nordic Drugs 10 mg

10 mg

Film coated tablet

Oral

Norway

Nordic Drugs AB,

Box 30035

S-200 61 Limhamn

Acura

10 mg

Film coated tablet

Oral

Sweden

Nordic Drugs AB

Box 300 35

S-200 61 Limhamn

Acura

10 mg

Film coated tablet

Oral


ANNEX IV

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE DERMAPHARM 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Austria

Dermapharm GmbH

Türkenstr. 25/12

A-1090 Wien

Cetiderm 10 mg Filmtabletten

10 mg

Film coated tablet

Oral

Belgium

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetirizine dihydrochloride Dermapharm 10 mg filmomhulde tabletten

10 mg

Film coated tablet

Oral

Germany

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetiderm 10 mg Filmtabletten

10 mg

Film coated tablet

Oral

Netherlands

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetirizine dihydrochloride Dermapharm 10 mg tabletten

10 mg

Film coated tablet

Oral


ANNEX V

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE APEX 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Belgium

Docpharma N.V.

Ambachtenlaan 13 H

B-3001 Heverlee

Doccetiri

10 mg

Film coated tablet

Oral

Luxembourg

Docpharma N.V.

Ambachtenlaan 13 H

B-3001 Heverlee

Doccetiri-10

10 mg

Film coated tablet

Oral

Netherlands

Apex Pharmaceuticals Ltd.

2nd Floor, Devlin House

36 Saint George Street

Mayfair

W1S 2FW London

United Kingdom

Cetirizine dihydrochloride-APEX 10 mg

10 mg

Film coated tablet

Oral